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Abstract
Definitive diagnosis of primary hyperoxaluria (PH) currently utilizes sequential
Sanger sequencing of the AGXT, GRPHR, and HOGA1 genes but efficacy is
unproven. This analysis is time-consuming, relatively expensive, and delays in
diagnosis and inappropriate treatment can occur if not pursued early in the
diagnostic work-up. We reviewed testing outcomes of Sanger sequencing in 200
consecutive patient samples referred for analysis. In addition, the Illumina Tru-
seq custom amplicon system was evaluated for paralleled next-generation
sequencing (NGS) of AGXT, GRHPR, and HOGA1 in 90 known PH patients.
AGXT sequencing was requested in all patients, permitting a diagnosis of PH1
in 50%. All remaining patients underwent targeted exon sequencing of GRHPR
and HOGA1 with 8% diagnosed with PH2 and 8% with PH3. Complete
sequencing of both GRHPR and HOGA1 was not requested in 25% of patients
referred leaving their diagnosis in doubt. NGS analysis showed 98% agreement
with Sanger sequencing and both approaches had 100% diagnostic specificity.
Diagnostic sensitivity of Sanger sequencing was 98% and for NGS it was 97%.
NGS has comparable diagnostic performance to Sanger sequencing for the diag-
nosis of PH and, if implemented, would screen for all forms of PH simulta-
neously ensuring prompt diagnosis at decreased cost.
Introduction
The primary hyperoxalurias (PH) are autosomal recessive
diseases (see Cochat and Rumsby 2013 for recent review)
of glyoxylate metabolism characterized by excessive
production of oxalate, which is excreted by the kidney.
Calcium oxalate crystallizes in the urine, leading to neph-
rocalcinosis, urolithiasis, and consequent renal failure if
treatment is not initiated promptly. The three known
types of PH are PH1, due to mutations in the AGXT gene
(Purdue et al. 1990), PH2, caused by mutations in
GRHPR (Cramer et al. 1999), and PH3 arising from
defects in HOGA1 (Belostotsky et al. 2010). The different
types of PH appear clinically very similar, with a similar
age of onset (Williams et al. 2012) although treatment
choices vary according to type, and it is, therefore, essen-
tial that an accurate diagnosis is established early in the
course of disease to guide appropriate and effective treat-
ment.
Diagnosis of PH currently relies upon stepwise Sanger
sequencing of the exons and flanking intronic regions of
the AGXT, GRHPR, and HOGA1 genes (Cregeen et al.
2003; Williams and Rumsby 2007; Williams et al. 2012).
This individual gene approach is costly and time-con-
suming and can contribute to delay in diagnosis,
negatively impacting upon disease outcome (Hoppe and
Langman 2003; van der Hoeven et al. 2012). Next gen-
eration sequencing (NGS) enables unrivaled sequencing
capacity to be obtained at significantly reduced cost and
faster turnaround time (Bockenhauer et al. 2012). Given
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these advantages, targeted NGS technologies are begin-
ning to replace Sanger sequencing in diagnostic settings.
However, it is essential to establish diagnostic validity
of these approaches prior to their routine diagnostic
use.
The University College London (UCL) Hospitals labo-
ratory has offered a DNA sequencing service for the diag-
nosis of PH since 2006. PH1 testing comprises a step 1
test in which exons 1, 4, and 7 are sequenced, followed
by analysis of the remaining exons (PH1 step 2) when
step 1 does not identify two disease-causing mutations.
Specimens testing negative for PH1, may progress to PH2
step 1 (exons 2 and 4 of GRHPR) and/or PH3 step 1
(exons 5 and 7 of HOGA1) followed by sequencing of the
remaining exons of these genes. This approach allows the
exons with the more common mutations to be sequenced
first, enabling a more rapid diagnosis at reduced cost in
some patients. Enzyme analysis is available for PH1 and
PH2 testing and may be pursued in those patients where
no mutations are detected, but requires a liver biopsy
specimen.
Diagnostic accuracy of DNA testing for PH1 has been
previously evaluated in liver biopsy proven patient
cohorts, but the diagnostic yield of DNA sequencing for
all three types of PH in the referral population has not
been previously evaluated. In this manuscript, we review
testing outcomes and diagnostic yield of Sanger sequenc-
ing of the AGXT, GRHPR, and HOGA1 genes in 200 con-
secutive patient samples referred to the UCL Hospitals
laboratory. In addition, we report an evaluation of the
Illumina Truseq custom amplicon (TSCA) assay for
simultaneous targeted NGS of the AGXT, GRHPR, and
HOGA1 genes in a retrospective analysis of 90 patients
diagnosed with PH.
Materials and Methods
Samples
Blood and DNA samples from 200 patients with clinical
symptoms suggestive of PH were referred for analysis.
Informed consent for genetic testing was obtained by
referring clinicians at time of patient work-up. The NGS
evaluation utilized genomic DNA samples from 90 PH
patients previously diagnosed by liver biopsy enzyme
analysis (n = 59) or DNA analysis (n = 31), with geno-
types determined by restriction digest analysis (Purdue
et al. 1990; von Schnakenburg and Rumsby 1997) and/or
Sanger sequencing (Cregeen et al. 2003; Williams and
Rumsby 2007; Williams et al. 2012). Samples were anony-
mized prior to NGS and bioinformatics analysis was con-
ducted by a researcher blinded to the initial patient
diagnoses and genotypes obtained.
Sanger sequencing
Genomic DNA was extracted from peripheral blood
leukocytes using the QIAamp DNA Blood Mini Kit (Qia-
gen, Manchester, UK) according to manufacturer’s instruc-
tions. AGXT, GRHPR, and HOGA1 were each amplified in
three large fragments by long-range polymerase chain reac-
tion (PCR) using suitably positioned primers (Cregeen
et al. 2003; Williams and Rumsby 2007; Williams et al.
2012). PCR products were cycle sequenced using internal
primers and analyzed using an ABI 310 Genetic Analyzer
(Applied Biosystems, Paisley, UK) as described previously
(Williams et al. 2012).
Evaluation of PH genetics service
Testing outcomes of Sanger sequencing were evaluated as
the number of pathological variants found in each step of
the analysis. The variants, their frequency, and exonic
location were noted. Nomenclature is based upon the
AGXT, GRHPR, and HOGA1 cDNA sequences (Genbank
Accession numbers NM_000030.2, NM_012203.1, and
NM_138413.3, respectively), following HGVS recommen-
dations (http://www.hgvs.org/), where nucleotide #1 is the
first nucleotide of the ATG start codon. Pathogenicity of
novel variants was assumed for splice-site and truncating
mutations. For missense variants, pathogenicity was
assigned based upon in silico prediction tools (SIFT,
polyphen 2, and mutation taster), data from the 1000 ge-
nomes project and for PH1 modeling on the AGT crystal
structure (Zhang et al. 2003). Diagnostic yield was
assessed by determining the proportions of referred
patients diagnosed with PH and via calculation of the
posttest probability of disease.
NGS targeted enrichment design
The TSCA kit (Illumina, San Diego, CA) was used to
select for genes of interest, and to prepare amplicons for
sequencing. The web-based Illumina DesignStudio was
used to design a custom mixture of oligonucleotide
probes, allowing sequencing of the genes of interest as
defined by their chromosomal coordinates. Since sequenc-
ing of the full 30-UTRs was not required, the 30 coordi-
nates of AGXT and HOGA1 were truncated. The
coordinates used in the design were as follows:
AGXT: 2:241808137 – 2:241818536
GRHPR: 9:37422707 – 9:37436986
HOGA1: 10:99344102 – 10:99371756
The DesignStudio software identified exonic regions
and designed probes to generate amplicons using the
following options: Exons only; amplicon length 250 bp;
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padding per exon: 25 bases; genome sequence: H. sapiens
UCSC hg19 primary assembly. This process identified 42
amplicons covering 5242 bp, including the full coding
regions and TCSA probes were synthesized by Illumina.
NGS sample preparation and sequencing
DNA concentration was determined using the Quant-iT
Broad-Range dsDNA Assay Kit (Invitrogen, Paisley, UK)
measured with a Qubit 2.0 Fluorometer (Invitrogen).
Quality and integrity were assessed by electrophoresis on a
0.8% agarose gel. Samples were prepared following the
TSCA protocol using 250 ng of template DNA per reac-
tion. Agencourt AMPure XP beads (Beckman Coulter, Inc.,
High Wycombe, UK) were used for PCR clean-up. Library
normalization was performed according to the TSCA pro-
tocol, and compatible indexed samples were pooled.
The pooled library was diluted into HT1 buffer (Illu-
mina) and spiked with PhiX (1%) prior to sequencing.
Products were sequenced in multiplexed sequencing runs
on the Illumina MiSeq generating 150 bp paired-end
reads. Sequences were demultiplexed using MiSeq Repor-
ter software allowing for one mismatch in the index
sequence.
NGS analysis
An initial test batch (n = 14) was analyzed to assess the
performance of the protocol, then a further application
batch with two patient samples from round one repeated,
alongside 76 additional patient samples. In total samples
from 64 PH1, 14 PH2, and 12 PH3 patients were ana-
lyzed, with one technical control and one negative control
included per batch. Diagnostic sensitivity and specificity
were determined and confidence intervals calculated using
standard statistical procedures (Agresti and Coull 1998).
NGS data analysis
Sequencing data from the MiSeq sequencer were exported
as fastq files. Run parameters were assessed using the
MiSeq Reporter and Amplicon Viewer applications (Illu-
mina). Sequencing read quality was assessed with FastQC
(http://www.bioinformatics.babraham.ac.uk/projects/fast-
qc). Reads were mapped to the GRCh37 (hg19) reference
assembly with BWA version 0.6.1 (Li and Durbin 2010).
Probe sequences were soft-clipped after alignment using
custom Java code.
Indel realignment, quality score recalibration, and vari-
ant calling were carried out with the Genome Analysis
Toolkit (GATK) version 2.6-5 (McKenna et al. 2010).
Variants were called with the GATK Unified Genotyper
algorithm considering only bases with a minimum base
call quality score Qphred of 20. Raw variant calls were hard
filtered applying a coverage threshold of >30X and minor
allele frequency of >15%. Functional annotation of vari-
ants was carried out with ANNOVAR (Wang et al. 2010)
and SeattleSeq version 8 (http://snp.gs.washington.edu).
The Integrative Genomics Viewer version 2.2 (Robinson
et al. 2011) was used for visual inspection of read and
variant data.
Results
Evaluation of PH genetics service
Over a 5-year period, 200 patient samples were referred
to the PH Genetics Service for diagnosis by Sanger
sequencing. The mutations found are listed in Table 1.
PH1 step 1 analysis identified two mutations in 52 (26%)
patients (Table 1A). One mutation was found in 14
patients and in all cases the second mutation was detected
by step 2 analysis (Table 1B). All patients who were nega-
tive on step 1 analysis progressed to step 2 analysis, with
two mutations detected in 34 patients (Table 1C). Thus,
step 2 analysis established a diagnosis in 48 (24%)
patients.
Of the AGXT mutations detected, the exon 4 mutation
c.508G>A represented 61 of 200 (31%) mutant alleles. The
next most frequent mutation was the exon 1 mutation
c.33dupC, found in 25 of 200 (13%) of mutant alleles. Of
all mutant alleles identified, 46% were in exon 4 and 17%
in exon 1, with only 3.5% in exon 7, the third exon ana-
lyzed in the step 1 test. In light of this finding, exon 7
sequencing has been removed from the PH1 step 1 test.
All 100 patients who tested negative for PH1 pro-
gressed to PH2 and PH3 step 1 testing, with the out-
comes shown in Table 2. Of these, 14 patients (7%) were
found to have two PH2 mutations (Table 2A) and 14
patients (7%) had two PH3 mutations (Table 2B). One
mutation was found in GRHPR in two patients and in
HOGA1 in two patients. In each case, the second muta-
tion was detected by step 2 analysis. Therefore, in total 16
patients (8%) were diagnosed with PH2 and 16 patients
(8%) were diagnosed with PH3.
Of those testing negative on the PH2 and PH3 step 1
tests, 27 patients progressed to PH2 step 2, of whom 16
also progressed to PH3 step 2. No further mutations
were detected as a result of these analyses. Eleven
patients progressed to liver biopsy analysis for alanine:
glyoxylate aminotransferase and glyoxylate reductase
activities, with PH1 and PH2 excluded in ten of these
and PH1 confirmed in one. In this patient, exhaustive
genetic analysis and family studies revealed a large AGXT
gene deletion on one allele, but the other mutation was
not detected.
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The prevalence of the three forms of PH in the UCL
Hospitals referral population has previously been estimated
to be 0.63, 0.15, and 0.09, respectively (Williams et al.
2012). Prevalence of disease in the referral population
equates to the pretest probability of disease. Sensitivities of
the PH1 step 1 and PH1 step 2 tests were 65.3% (66 of 101
cases) and 99% (100 of 101 cases), respectively. Applying
Bayes theorem, the finding of a pathological variant in PH1
step 1 or step 2 increases posttest probability of PH1 to
0.99. If no mutation is found in step 1, then the posttest
probability is 0.37. If no mutation is found in step 2, the
probability of disease falls to 0.017. Of the population pre-
viously referred for liver biopsy analysis, 3% were diag-
nosed with PH2, less than the 7% who tested positive by
DNA analysis. This may reflect the fact that patients with
suspected PH2 and increased L-glyceric acid excretion
tended not to undergo liver biopsy analysis (Rumsby et al.
2004). Of 200 patient samples tested, 51 did not undergo
complete sequencing of all three genes, leaving the diagno-
sis unresolved in 25% of patients referred.
TruSeq custom amplicon targeted
enrichment
To evaluate the TruSeq targeted enrichment assay, a total
of 90 DNA samples were analyzed in two multiplexed
Table 1. Outcomes of PH1 step 1 and step 2 testing in 200 consecu-
tive samples referred for Sanger sequencing.
Allele 1 Allele 2 No. of patients
(A) 2 mutations found in step 1 test
c.508G>A c.508G>A 19
c.33dupC c.33dupC 8
c.508G>A c.33dupC 5
c.508G>A c.466G>A 3
c.447_454del8 c.447_454del8 2
c.731T>C c.731T>C 2
c.508G>A c.697C>T 1
c.508G>A c.424-2A>G 1
c.508G>A c.121G>A 1
c.508G>A c.122G>A 1
c.508G>A c.116_117dupCA 1
c.454T>A c.116_117dupCA 1
c.454T>A c.454T>A 1
c.454T>A c.466G>A 1
c.33dupC c.107G>A 1
c.33dupC c.481G>A 1
c.77T>C c.77T>C 1
c.473C>T c.473C>T 1
c.725dupT c.725dupT 1
(B) 1 mutation found in step 1 test, 1 mutation found in step 2 test
c.33dupC c.614C>T 1
c.33dupC c.866G>A; c.1076T>C 1
c.121G>A c.846+1G>A 1
c.454T>A c.353G>A 1
c.508G>A c.568G>A 1
c.508G>A c.570delG 1
c.508G>A c.614C>T 1
c.508G>A c.653C>T 1
c.508G>A c.777-1G>C 1
c.508G>A c.834delC 1
c.508G>A c.846+1G>T 2
c.508G>A c.847-3C>G 1
c.508G>A c.1014C>G 1
(C) 2 mutations found in step 2 test
c.1049G>A c.1049G>A 5
c.302T>C c.302T>C 3
c.519_520delinsGA c.519_520delinsGA 3
c.245G>A c.245G>A 2
c.584T>G c.584T>G 2
c.596-2A>G c.596-2A>G 2
c.614C>T c.614C>T 2
c.853G>T c.853G>T 2
c.187G>C c.187G>C 1
c.322T>C c.322T>C 1
c.324G>T c.324G>T 1
c.346G>A c.346G>A 1
c.577dupC c.577dupC 1
c.577dupC c.847-3C>G 1
c.577delC c.1079G>A 1
c.680+1G>C c.680+1G>C 1
c.777-2A>G c.777-2A>G 1
c.798_802del c.798_802del 1
c.851T>C c.851T>C 1
c.922C>T c.922C>T 1
c.1007T>A c.1007T>A 1
Novel variants are shown in bold. PH, primary hyperoxaluria.
Table 2. Outcomes of PH2 and PH3 step 1 and step 2 testing.
Allele 1 Allele 2 No. of patients
(A) PH2 testing
c.103delG c.103delG 4
c.494G>A c.494G>A 3
403_404+2delAAGT 403_404+2delAAGT 3
84-8_84-5delCCCC;
84-13_84-12delCC
84-8_84-5delCCCC;
84-13_84-12delCC
1
c.103delG c.288-2delAGT 1
c.102G>A c.965T>C 1
c.295C>T c.493+2T>A 1
c.494G>A c.203T>C 1
c.743T>A c.743T>A 1
(B) PH3 testing
c.700+5G>T c.700+5G>T 8
c.107C>T c.700+5G>T 1
c.107C>T c.860G>T 1
c.110G>T c.953G>A 1
c.700+5G>T c.907C>T 1
c.700+5G>T c.944_946delAGG 1
c.860G>T c.944_946del AGG 1
c.875T>C c.875T>C 1
c.208C>T c.700+5G>T 1
All patients who tested negative for PH1 progressed to PH2 and PH3
Step 1 testing. PH2 step 2 and PH3 step 2 testing was performed in
43 and 32 patients, respectively, as requested by the referring clini-
cians. Novel variants are shown in bold. PH, primary hyperoxaluria.
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sequencing runs on the Illumina MiSeq. In order to dem-
onstrate scalability of the assay, 14 samples were
sequenced in the first run and 78 in the second run. Alto-
gether 23,338,572 150 bp reads were generated in the first
run and 21,023,972 in the second run, equating to an
average theoretical amplicon coverage of 24,268X and
3924X, respectively. After read mapping, clipping of probe
sequences and quality filtering, the average depth of
amplicon coverage was 21,092X and 3419X for samples in
the first and second runs, respectively. The minimum
average amplicon coverage was 6364X in the first run and
929X in the second, while the highest average amplicon
coverage was 44,436X and 6927X, respectively (Fig. 1).
Two samples were sequenced in both runs allowing
assessment of the impact of sequencing depth on variant
detection. No differences were observed in the between-
run base call and consequent variant detection for these
two samples. Full exomic coverage of the genes of interest
was achieved in both runs with sequence coverage extend-
ing to at least 55 bases upstream of the exons and at least
60 bases downstream.
The results of NGS analysis and previous DNA analysis
are compared in Table 3. Of 175 disease-causing alleles pre-
viously identified in the patient cohort, NGS analysis
detected 174, the exception being a missense c.346G>A
mutation in AGXT exon 3. The range of mutations for
which the detection ability of NGS was tested included
seven splice-site mutations (four in AGXT, two in GRHPR,
and one in HOGA1), 16 indels (10 in AGXT, four in
GRHPR, and two in HOGA1), and 39 missense/nonsense
mutations (29 in AGXT, four in GRHPR, and six in
HOGA1). These mutations included previously unpub-
lished variants in AGXT; c.209C>A, c.215dupA, c.473delC,
c.533G>A, c.996G>A, c.680+2T>A, c.847-1G>A and
c.1045G>A, GRHPR; c.45delA, c.102G>A, c.493+2T>A,
c.905G>A and c.965T>C and HOGA1; c.158delA.
NGS analysis was able to accurately determine muta-
tion zygosity in the majority of cases, with exception of
two AGXT mutations in exon one of the gene;
c.116_117dupCA and c.121G>A, which were base called
as homozygous although they were present in heterozy-
gous state. Three patients diagnosed with PH1 were also
heterozygous for the high-frequency HOGA1 splice-site
mutation c.700+5G>T.
There were no false positive diagnoses of disease; thus,
the NGS assay showed 100% (95% CI ≥98%) diagnostic
specificity. For PH1, diagnostic sensitivity was 97% (95%
CI; 95–99) for Sanger sequencing and 95% (95% CI; 92–
98) for NGS. For PH2 and PH3 both approaches had
100% (95% CI ≥98%) diagnostic sensitivity. The overall
diagnostic sensitivity of Sanger sequencing was 98% (95%
CI; 96–100). For NGS, it was 97% (95% CI; 95–99), giv-
ing the two sequencing approaches comparable diagnostic
performance.
Minor allele status of AGXT could be assessed for all
patients. This is particularly relevant for those with PH1
since several mutations, most notably c.508G>A, have
increased pathogenicity when associated with the minor
allele (see Williams et al. 2009 for review). Although it
was originally reported that the c.32C>T, c.264C>T, and
c.1020A>G variants are in complete linkage disequilib-
rium, it has since been established that the linkage breaks
down in some cases, as reviewed in Williams et al. 2009.
In our study, c.32C>T and c.264C>T were found in link-
age disequilibrium in all homozygotes detected, but in
five patients the copy number of c.1020A>G varied from
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Figure 1. Depth of coverage. Amplicon coverage achieved when multiplexing 14 samples (run 1) or 78 samples (run 2) per MiSeq run. (A)
Theoretical average coverage (calculated for each sample as total number of reads 9 read length/total target length). (B) Distribution of observed
amplicon coverage after read mapping, clipping of probe sequences, and quality filtering.
73ª 2014 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
E. L. Williams et al. NGS vs Sanger Sequencing for the Diagnosis of PH
Table 3. Comparison of the results of NGS and previous DNA analysis.
Genotype by Sanger sequencing
or restriction digest
Detected
by NGS
Variant
reads (%)
Variant
effect
No. of
patients
PH1 patients
c.2_3delinsAT; c.33dupC Yes; Yes 73;26 p.Met1Asn; p.Lys12fs 1
c.32_33delCC; c.1045G>A Yes; Yes 30;62 p.Pro11fs; p.Gly349Ser 1
c.33dupC; c.33dupC Yes; Yes 96 p.Lys12fs; p.Lys12fs 3
c.33dupC; c.454T>A Yes; Yes 53;47 p.Lys12fs; p.Phe152Ile 1
c.33dupC; c.508G>A Yes; Yes 52;29 p.Lys12fs; p.Gly170Arg 2
c.33dupC; c.547G>A Yes; Yes 46;51 p.Lys12fs; p.Asp183Asn 1
c.33dupC; c.846G>C Yes; Yes 44;56 p.Lys12fs; p.Gln282His 1
c.33dupC; c.886_888delGCG Yes; Yes 48;49 p.Lys12fs; p.Ala296del 1
c.302T>C; c.302T>C Yes; Yes 100 p.Leu101Pro; p.Leu101Pro 1
c.423G>T; c.423G>T Yes; Yes 97 p.Glu141Asp; p.Glu141Asp 1
c.447_454delGCTGCTGT;
c.447_454delGCTGCTGT;
Yes; Yes 100 p.Leu151fs; p.Leu151fs 2
c.481G>T; c.614C>T Yes; Yes 25;53 p.Gly161Cys; p.Ser205X 1
c.508G>A; c.106C>T Yes; Yes 49;41 p.Gly170Arg; p.Arg36Cys 1
c.508G>A; c.116_117dupCA Yes; Yes* 44;99 p.Gly170Arg; p.Ala40fs 1
c.508G>A; c.121G>A Yes; Yes* 46;95 p.Gly170Arg; p.Gly41Arg 2
c.508G>A; c.209C>A Yes; Yes 49;54 p.Gly170Arg; p.Thr70Asn 1
c.508G>A; c.215dupA Yes; Yes 45;56 p.Gly170Arg; p.Asn72fs 1
c.508G>A; c.322T>C Yes; Yes 49;35 p.Gly170Arg; p.Trp108Arg 1
c.508G>A; c.454T>A Yes; Yes 55;49 p.Gly170Arg; p.Phe152Ile 2
c.508G>A; c.508G>A Yes; Yes 99 p.Gly170Arg; p.Gly170Arg 4
c.508G>A; c.533G>A Yes; Yes 44;47 p.Gly170Arg; p.Cys178Tyr 1
c.508G>A; c.577dupC Yes; Yes 46;47 p.Gly170Arg; p.Leu193fs 1
c.508G>A; c.653C>T Yes; Yes 52;64 p.Gly170Arg; p.Ser218Leu 1
c.508G>A; c.697C>T Yes; Yes 50;43 p.Gly170Arg; p.Arg233Cys 1
c.508G>A; c.731T>C Yes; Yes 46;47 p.Gly170Arg; p.Ile244Thr 1
c.508G>A; c.738G>A Yes; Yes 45;48 p.Gly170Arg; p.Trp246X 1
c.508G>A; c.847-3C>G Yes; Yes 49;48 p.Gly170Arg; mis-splicing 2
c.508G>A; c.943-1G>T Yes; Yes 46;52 p.Gly170Arg; mis-splicing 1
c.508G>A; c.996G>A Yes; Yes 45;17 p.Gly170Arg; p.Trp332X 1
c.508G>A; unk Yes; unk 49 p.Gly170Arg; unk 1
c.508G>A; c.473delC Yes; Yes 57;40 p.Gly170Arg; p.Ser158fs 1
c.508G>A; c.1076T>C Yes; Yes 47;57 p.Gly170Arg; p.Leu359Pro 1
c.560C>T; c.560C>T Yes; Yes 100 p.Ser187Phe; p.Ser187Phe 1
c.577dupC; c.847-3C>G Yes; Yes 51;47 p.Leu193fs; mis-splicing 1
c.568G>A; c.568G>A Yes; Yes 99 p.Gly190Arg; p.Gly190Arg 2
c.584T>G; c.584T>G Yes; Yes 100 p.Met195Arg; p.Met195Arg 1
c.661T>C; c.661T>C Yes; Yes 98 p.Ser221Pro; p.Ser211Pro 1
c.680+2T>A; c.346G>A Yes; No 58;10 Mis-splicing; p.Gly116Arg 1
c.697C>T; c.697C>T Yes; Yes 100 p.Arg233Cys; p.Arg233Cys 1
c.698G>A; c.466G>A Yes; Yes 55;80 p.Arg233His; p.Gly156Arg 1
c.698G>A; c.603C>A Yes; Yes 55;53 p.Arg233His; p.Asp201Glu 1
c.731T>C; c.248A>G Yes; Yes 48;54 p.Ile244Thr; p.His83Arg 1
c.731T>C, c.731T>C Yes; Yes 99 p.Ile244Thr; p.Ile244Thr 3
c.731T>C; c.847-3C>G Yes; Yes 45;54 p.Ile244Thr; mis-splicing 1
c.798_802 delinsACAATCTCAG;
c.798_802 delinsACAATCTCAG
Yes; Yes 100 p.Ile267fs; p.Ile267fs 1
c.822G>C; c.822G>C Yes; Yes 99 p.Glu247Asp; p.Glu247Asp 1
c.847-1G>A; c.847-1G>A Yes; Yes 99 mis-splicing; mis-splicing 1
c.976delG; c.976delG Yes; Yes 100 p.Val326fs; p.Val326fs 1
c.1049G>A; c.1049G>A Yes; Yes 99 p.Gly350Asp; p.Gly350Asp 1
unk; unk unk; unk unk; unk 1
PH2 patients
c.102G>A; c.965T>C Yes; Yes 51;54 p.Trp34X; p.Met322Thr 1
74 ª 2014 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
NGS vs Sanger Sequencing for the Diagnosis of PH E. L. Williams et al.
that of the other two variants. Additionally, data from the
1000 genomes project reveal different minor allele fre-
quencies (0.108, 0.109, and 0.137, respectively) for these
variants, suggesting that the c.1020A>G variant is more
frequent than c.32C>T and c.264C>T.
Discussion
Our review of genetic testing outcomes of 200 consecutive
patients’ samples analyzed by Sanger sequencing found
50% diagnosed with PH1, 8% with PH2, and 8% with
PH3. Of the patients referred, all three genes were
sequenced in a further 8%, with no mutations detected.
One patient with negative DNA results was diagnosed
with PH1 by liver biopsy analysis. In the remaining 25%
of patients, step 2 sequencing of the PH2 and PH3 genes
was not requested, leaving their diagnosis unresolved.
These findings prompted us to evaluate an NGS approach
for simultaneous sequencing of all three genes within a
single diagnostic test. This approach would ensure that all
patients are screened for all three genetic causes of the
disease early in their diagnostic work-up, enabling a more
rapid diagnosis.
Genomic DNA samples from 90 PH patients were ana-
lyzed by NGS. Sanger sequencing of these samples had
previously identified both disease-causing mutations in 88
patients. NGS analysis detected both disease-causing
mutations in 87 of these. In the two remaining patients,
both with liver biopsy proven PH1, neither approach
detected two disease-causing mutations. Targeted NGS
identified a variety of mutations including minor indels,
but was not tested on its ability to pick up major dele-
tions, relatively uncommon in these disorders. From
analysis of other genes, including CFTR (Abou Tayoun
et al. 2013) and LDLR (Vandrovcova et al. 2013) one
might expect reduced copy number. The ability to detect
large deletions could be assessed in future iterations of
the assay design and with tailoring of the bioinformatics
analysis.
NGS results showed 98% agreement with Sanger
sequencing, with only four of 180 variants showing dis-
crepant base calling. These exceptions all occurred in the
AGXT gene and included a c.346G>A heterozygous
change not identified by NGS in one patient. Interroga-
tion of read mapping data revealed that this mutation
was actually present in 10% of sequencing reads, suggest-
ing that differential amplification of the two alleles in this
region produced incorrect base calling. The other discrep-
ancies occurred in three patients with mutations in exon
one, where heterozygous variants were incorrectly called
as homozygous; c.116_117dupCA in one patient and
c.121G>A in two patients. These patients did not harbor
any single nucleotide polymorphisms (SNPs) in the bind-
ing regions of the exon one sequencing probes, suggesting
Table 3. Continued.
Genotype by Sanger sequencing
or restriction digest
Detected
by NGS
Variant
reads (%)
Variant
effect
No. of
patients
c.103delG; c.103delG Yes; Yes 100 p.Asp35fs; p.Asp35fs 2
c.103delG; c.84-2A>G Yes; Yes 51;46 p.Asp35fs; mis-splicing 1
c.103delG; c.905G>A Yes; Yes 100 p.Asp35fs; p.Arg302His 1
c.295C>T; c.493+2T>A Yes; Yes 52;55 p.Arg99X; mis-splicing 1
c.403_404+2delAAGT; c.403_404+2delAAGT Yes; Yes 100 mis-splicing 2
c.403_404+2delAAGT; c.540delT Yes; Yes 26;34 mis-splicing 1
c.45delA; c.45delA Yes; Yes 100 p.Ala17fs; p.Ala17fs 1
c.494G>A; c.494G>A Yes; Yes 100 p.Gly165Asp; p.Gly165Asp 3
c.84-2A>G; c.84-2A>G Yes; Yes 100 mis-splicing 1
PH3 patients
c.107C>T; c.860G>T Yes; Yes 49;16 p.Ala36Val; p.Gly287Val 1
c.346C>T; c.346C>T Yes; Yes 96 p.Gln116X; p.Gln116X 1
c.700+5G>T; c.158delA Yes; Yes 58;28 mis-splicing; p.Asp53fs 1
c.700+5G>T; c.208C>T Yes; Yes 50;49 mis-splicing; p.Arg70X 1
c.700+5G>T; c.700+5G>T Yes; Yes 100 mis-splicing 3
c.700+5G>T; c.907C>T Yes; Yes 56;34 mis-splicing; p.Arg303Cys 1
c.860G>T; c.944_946delAGG Yes; Yes 16;16 p.Gly287Val; p.Glu315del 1
c.875T>C; c.875T>C Yes; Yes 100 p.Met292Thr; p.Met292Thr 1
c.944_946delAGG; c.944_946delAGG Yes; Yes 100 p.Glu315del; p.Glu315del 2
For variants detected in multiple patients, the mean result is shown for % variant reads. The asterisk (*) indicates the two variants incorrectly
assigned as homozygous by the NGS base calling. Novel variants are shown in bold. NGS, next generation sequencing; PH, primary hyperoxaluria.
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that preferential allele amplification was not the cause.
Inspection of NGS read mapping data revealed a region
of lower read depth spanning c.96-138, typically 40–60%
of the surrounding regions, reflecting the fact that this
area is only covered by one amplicon in the design. How-
ever, the read depth in this region of affected samples was
over 4009, which should be sufficient for accurate variant
calling. Future iterations of TSCA design should be
altered to optimize coverage in these regions.
Targeted NGS showed comparable diagnostic perfor-
mance to Sanger sequencing with sufficient test sensitivity
and specificity for a clinical diagnostic assay. Similar diag-
nostic performance has been observed for other targeted
NGS studies, including CFTR gene analysis for the diag-
nosis of cystic fibrosis (Abou Tayoun et al. 2013), BRCA1
and BRCA2 gene sequencing for hereditary breast and
ovarian cancer (Feliubadalo et al. 2013), and a gene panel
for the diagnosis of familial hypercholesterolemia (Van-
drovcova et al. 2013). Targeted NGS analyses are not
prone to difficulties currently encountered in whole gen-
ome sequencing (WGS), including areas of poor coverage,
accuracy, and cost of after-sequencing bioinformatics
analysis (reviewed in Chrystoja and Diamandis 2014). In
addition, scalability of the assay has been demonstrated,
enabling a diagnostic service to be provided without com-
promising cost or turnaround time. The availability of
curated mutation databases for the three disorders
(http://www.uclh.nhs.uk/phmd), would also assist with
streamlined identification of pathological and nonpatho-
logical variants.
In all three known types of PH, there is usually signifi-
cant hyperoxaluria, with excretion levels typically exceed-
ing >0.7 mmol/1.73 m2 per 24 h (upper limit of normal
0.46). Not all patients with pronounced hyperoxaluria
and high clinical suspicion of PH receive genetic testing.
In the Netherlands, a retrospective review of 25 patients
with elevated urine oxalate excretion identified one previ-
ously undiagnosed case of PH1 (van Woerden et al.
2007). A recent review of >5000 analyses performed in
the UCL Hospitals laboratory revealed that genetic diag-
nosis of PH was not pursued in 24 patients, despite sig-
nificantly elevated urine oxalate (Clifford-Mobley et al.
2014). Prompt diagnosis of PH is essential for timely
treatment to preserve renal function, delay onset of renal
failure, and limit oxalosis (Milliner 2005). There is, there-
fore, a clinical need for rapid and affordable screening for
all forms of PH in stone-forming patients with grossly
elevated oxalate excretion.
It is evident that delays in diagnosis of PH are com-
mon. In a survey of PH diagnosis, treatment and patient
outcome in the United States fewer than half of patients
underwent liver biopsy enzyme analysis for definitive
diagnosis. Of those with a definitive diagnosis, 30% were
diagnosed already in end-stage renal failure (Hoppe and
Langman 2003). This picture is no different elsewhere; in
a study of Dutch PH1 patients, 38% went undiagnosed
until adulthood, 52% already in end-stage renal failure.
Importantly, 68% of these patients were homozygous for
the p.Gly170Arg mutation, which has a favorable progno-
sis when pyridoxine therapy is started early (Harambat
et al. 2009; van der Hoeven et al. 2012).
This is the first study in which all three PH-causative
genes have been analyzed in a large cohort of PH
patients. Interestingly, three PH1 patients were heterozy-
gous for the common HOGA1 splice-site mutation
c.700+5G>T. This is somewhat higher than would be
expected, given the allele frequency was found to be only
0.09% in the 1000 genomes project. PH1 is known to be
a clinically heterogeneous condition, which may in part
arise from natural variation in other genes involved in
related metabolic pathways. A previous study identified
three idiopathic stone formers were heterozygous for vari-
ants in the HOGA1 gene, including the c.860G>T muta-
tion (Monico et al. 2011). HOGA1 variants may possibly
play a modifier role in disease expression in PH1 and this
may become clearer as more patients have all three PH
genes sequenced during their diagnostic work-up.
The identification of pathogenic variants in more than
one of the genes associated with PH highlights one of the
disadvantages of sequential analysis, wherein finding a
single pathological mutation may lead one to incorrectly
assume a diagnosis. A PH3 case has been reported in
which the proband had a family history of PH1 and this
patient was symptomatic for PH, despite carrying only
one of the familial AGXT mutations. Full sequencing of
the AXGT gene did not identify further likely PH1-caus-
ing variants, but subsequent analysis of HOGA1 identified
two disease-causing variants, leading to eventual diagnosis
of PH3 (Beck et al. 2013).
In conclusion, targeted NGS analysis compared favor-
ably with Sanger sequencing showing 98% agreement for
the genotypes detected, with similar diagnostic perfor-
mance. In two liver biopsy proven PH1 patients, neither
Sanger sequencing nor NGS detected any mutations.
Their disease may be due to promoter defects, or a result
of sequence changes deep within introns leading to activa-
tion of cryptic splice sites. Since these regions are not
covered by current sequencing approaches, in such cases
liver biopsy enzyme analysis would still be required to
confirm disease. Targeted NGS has potential to offer a
cost-effective, scalable test for all three types of PH,
enabling more rapid diagnosis than Sanger sequencing.
NGS yielded additional information, including the simul-
taneous identification of variants in more than one of the
PH genes. The implications of this finding for disease
phenotype and patient prognosis may become clearer as
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routine genetic diagnostic testing embraces the next gen-
eration of DNA sequencing.
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